Teva Pharmaceutical Industries Limited vs Pharming Group N.V.: Examining Key Revenue Metrics

Teva vs. Pharming: A Decade of Revenue Dynamics

__timestampPharming Group N.V.Teva Pharmaceutical Industries Limited
Wednesday, January 1, 20142576243920272000000
Thursday, January 1, 20151183827819652000000
Friday, January 1, 20161669366021903000000
Sunday, January 1, 201710751733522385000000
Monday, January 1, 201815457561118854000000
Tuesday, January 1, 201918933372116887000000
Wednesday, January 1, 202022839466616658000000
Friday, January 1, 202118985303715878000000
Saturday, January 1, 202220562200014925000000
Sunday, January 1, 202324531600015846000000
Monday, January 1, 202416544000000
Loading chart...

Unlocking the unknown

A Tale of Two Pharmaceutical Giants: Teva vs. Pharming

In the ever-evolving pharmaceutical landscape, Teva Pharmaceutical Industries Limited and Pharming Group N.V. stand as intriguing case studies. Over the past decade, Teva has consistently outperformed Pharming in terms of revenue, boasting figures nearly 100 times greater. However, the narrative is not solely about size. From 2014 to 2023, Pharming's revenue surged by an impressive 850%, while Teva experienced a decline of approximately 22%.

This shift highlights the dynamic nature of the industry, where smaller players can rapidly gain ground. In 2023, Pharming reached its highest revenue, marking a 19% increase from the previous year. Meanwhile, Teva's revenue showed signs of stabilization, with a slight uptick of 6% from 2022. As the pharmaceutical sector continues to innovate, these trends underscore the importance of agility and adaptation in maintaining market relevance.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025